SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001104659-24-043079 from Outlook Therapeutics, Inc. (OTLK)

Outlook Therapeutics, Inc.
Date: April 3, 2024 · CIK: 0001649989 · Accession: 0001104659-24-043079

AI Filing Summary & Sentiment

File numbers found in text: 333-278340

Date
April 3, 2024
Author
Not clearly detected
Form
CORRESP
Company
Outlook Therapeutics, Inc.

Letter

OUTLOOK THERAPEUTICS, INC.

485 Route 1 South

Building F, Suite 320

Iselin, New Jersey 08830

(609) 619-3990

April 3, 2024

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Re: Outlook Therapeutics, Inc.

Registration Statement on Form S-3

Filed March 28, 2024

File No. 333-278340

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-278340) (the “Registration Statement”) to become effective on Friday, April 5, 2024, at 4:00 p.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes Yvan-Claude Pierre of Cooley LLP, counsel to the Registrant, to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Yvan-Claude Pierre of Cooley LLP, counsel to the Registrant, at (212) 479-6721, or in his absence Courtney Tygesson of Cooley LLP at (312) 881-6680.

Very truly yours,
OUTLOOK THERAPEUTICS, INC.

Show Raw Text
CORRESP
1
filename1.htm

OUTLOOK THERAPEUTICS, INC.

485 Route 1 South

Building F, Suite 320

Iselin, New Jersey 08830

(609) 619-3990

April 3, 2024

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

  Re:
  Outlook Therapeutics, Inc.

Registration Statement on Form S-3

Filed March 28, 2024

File No. 333-278340

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended,
the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the
 “Commission”) take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-278340)
(the “Registration Statement”) to become effective on Friday, April 5, 2024, at 4:00 p.m., Eastern Time, or
as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission
(the “Staff”). The Registrant hereby authorizes Yvan-Claude Pierre of Cooley LLP, counsel to the Registrant,
to make such request on its behalf.

Once the Registration Statement has been declared effective, please
orally confirm that event with Yvan-Claude Pierre of Cooley LLP, counsel to the Registrant, at (212) 479-6721, or in his absence Courtney
Tygesson of Cooley LLP at (312) 881-6680.

Very truly yours,

OUTLOOK THERAPEUTICS, INC.

    By:
    /s/ Lawrence A. Kenyon

    Name:   Lawrence A. Kenyon

    Title:     Chief Financial Officer, Treasurer and Secretary

cc: Yvan-Claude Pierre, Cooley LLP

Courtney Tygesson,
Cooley LLP